Representative Investments

Through the various investment vehicles managed by 10K Lakes Capital and Sightline Partners, we have had the opportunity to invest in high-quality companies across the healthcare space. Here is a subset of our portfolio companies that have completed successful exits through M&A or IPO.

7

Acquired By Boston Scientific in 2011

Atritech’s WATCHMAN® Left Atrial Appendage Closure Technology is the first FDA-approved device to offer an alternative to anticoagulant drugs for patients experiencing atrial fibrillation who are at high risk for stroke. In 2011, Boston Scientific acquired Atritech for total consideration of up to $375 million.

Acquired by Vertex Pharma in 2019

Semma’s proprietary cell therapy technology has the potential to transform the treatment of diabetes in insulin dependent patients. The company focuses on using stem-cell derived human islets as a possible cure for type 1 diabetes. In 2019, Vertex Pharma acquired Semma for total consideration of $950 million.

NASDAQ: ACCD IPO in 2020

Accolade provides personalized health and benefit solutions designed to help millions of people and their employers navigate the complexities of the healthcare system while lowering the cost of care and improving health outcomes. In 2020, Accolade raised $220 million in an initial public offering and is listed on the NASDAQ under the ticker symbol ACCD.

Acquired By Werfen in 2017

Accriva is a leader in point-of-care (PoC) diagnostics for coagulation. Accriva’s suite of PoC diagnostic tests help to improve decision making regarding coagulation and platelet aggregation in a way that optimizes treatment outcomes and the overall cost of hospital treatments. In 2017, Werfen acquired Accriva for total consideration of up to $380 million.

NASDAQ: SWAV IPO in 2019

Shockwave is a medical device company that engages in developing and commercializing intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases. In 2019, Shockwave raised $97 million in an initial public offering.

NASDAQ: LYRA IPO in 2020

Lyra Therapeutics, a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. In 2020, Lyra raised $56 million in an initial public offering and is listed on the NYSE under the ticker symbol LYRA.

NYSE: VAPO IPO in 2018

Vapotherm, Inc. is a global medical technology company focused on the development and commercialization of its high velocity nasal insufflations (Hi-VNI) technology products used to treat patients suffering from respiratory distress. In 2018, Vapotherm raised $56 million in an IPO and is listed on the NYSE under the ticker symbol VAPO.

Acquired by Zoll Medical in 2021

Itamar Medical is a medical technology company focused on the development and commercialization of non-invasive medical devices and solutions to aid in the diagnosis of respiratory sleep disorders, including sleep apnea. In December 2021, Itamar Medical was acquired by Zoll Medical for $538 million.

$2.8B SPAC Merger with NYSE: LGV

Heartflow develops a cardiac diagnostic platform designed to transform the diagnosis and management of coronary artery diseases. The company’s platform uses data from standard CT scan to create a personalized 3D model of arteries and analyzes the impact of blockages on blood flow, enabling clinicians to treat patients with significant coronary artery disease while reducing unnecessary invasive testing.